Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.4 per share a year ago.
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.81, moving 2.35% from the previous trading session.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.95, marking a -5.71% move from the previous day.
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.43, signifying a -1.68% move from its prior day's close.
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?
Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, indicating a +2.41% shift from the previous trading day.
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
